Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases

被引:38
作者
Asano, T
Nakamura, H [1 ]
Uehara, Y
Yamamoto, Y
机构
[1] Gakushuin Univ, Fac Sci, Dept Chem, Tokyo 1718588, Japan
[2] Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808578, Japan
[3] Natl Inst Infect Dis, Dept Bioact Mol, Tokyo 1628640, Japan
关键词
bioorganic chemistry; boron; growth-factor receptors; tyrosine kinase inhibitor;
D O I
10.1002/cbic.200300748
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of aminoboronic acids was synthesized abased on the structure of lavendustin pharmocophore 1. Their inhibitory activities against the epidermal growth-factor receptor (EGFR) and vascular endothelial growth-factor receptor-1 (VEGFR-1, Flt-1) protein tyrosine kinases, and various protein kinases, PKA, PKC, PTK, and eEF2K were evaluated. Selective inhibition activities were observed in a series of aminoboronic acids. 4-Methoxy-3-((2-methoxyphenylamino)methyl)phenylboronic acid 10 inhibited EGFR tyrosine kinase, whereas 4-(2,5-dihydroxybenzylamino)phenyl boronic acid 72 inhibited Flt-1 protein kinase, although lavendustin pharmacophore 1 inhibited both EGFR and Flt-1 kinases at a compound concentration of 1.0 mug mL(-1). The selective inhibition of EGFR by 70 is considered to be due to the substitution of the dihydroxy groups on the benzyl moiety for a boronic acid group at the para position, whereas the selective inhibition of Flt-1 by 12 is due to the substitution of the carboxyl group on the aniline moiety in the lavendustin pharmacophore 1 for a boronic acid group.
引用
收藏
页码:483 / 490
页数:8
相关论文
共 37 条
[31]   1a-docosahexaenoyl mitomycin C: A novel inhibitor of protein tyrosine kinase [J].
Shikano, M ;
Onimura, K ;
Fukai, Y ;
Hori, M ;
Fukazawa, H ;
Mizuno, S ;
Yazawa, K ;
Uehara, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 248 (03) :858-863
[32]   Bifunctional peptide boronate inhibitors of thrombin: Crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide [J].
Skordalakes, E ;
Elgendy, S ;
Goodwin, CA ;
Green, D ;
Scully, MF ;
Kakkar, VV ;
Freyssinet, JM ;
Dodson, G ;
Deadman, JJ .
BIOCHEMISTRY, 1998, 37 (41) :14420-14427
[33]   The chemistry of neutron capture therapy [J].
Soloway, AH ;
Tjarks, W ;
Barnum, BA ;
Rong, FG ;
Barth, RF ;
Codogni, IM ;
Wilson, JG .
CHEMICAL REVIEWS, 1998, 98 (04) :1515-1562
[34]  
SUENAGA H, 1995, CHEM COMMUN, P29
[35]   Potentially macrocyclic peptidyl boronic acids as chymotrypsin inhibitors [J].
Tian, ZQ ;
Brown, BB ;
Mack, DP ;
Hutton, CA ;
Bartlett, PA .
JOURNAL OF ORGANIC CHEMISTRY, 1997, 62 (03) :514-522
[36]   Strategies toward the design of novel and selective protein tyrosine kinase inhibitors [J].
Traxler, P ;
Furet, P .
PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) :195-206
[37]   PROTON MAGNETIC-RESONANCE STUDIES OF THE ACTIVE-CENTER HISTIDINE OF CHYMOTRYPSIN COMPLEXED TO PEPTIDEBORONIC ACIDS - SOLVENT ACCESSIBILITY TO THE N-DELTA AND N-EPSILON SITES CAN DIFFERENTIATE SLOW-BINDING AND RAPIDLY REVERSIBLE INHIBITORS [J].
ZHONG, S ;
HAGHJOO, K ;
KETTNER, C ;
JORDAN, F .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (27) :7048-7055